Clinical Nuclear Medicine

Skip Navigation LinksHome > September 2013 - Volume 38 - Issue 9 > Metastatic Prostate Cancer Proven by 18F-FCH PET/CT Staging...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e31829b9d6b
Interesting Images

Metastatic Prostate Cancer Proven by 18F-FCH PET/CT Staging Scan in Patient With Normal PSA but High PSA Doubling Time

Hodolič, Marina MD*; Maffione, Anna Margherita MD; Fettich, Jure MD*; Gubina, Borut MD; Cimitan, Marino MD§; Rubello, Domenico MD

Collapse Box


Abstract: A 59-year-old man presented with frequent urination. Six months ago, his prostate-specific antigen (PSA) was 1.56 ng/mL; currently it is 3.5 ng/mL (PSA doubling time = 6 months; PSA velocity = 0.19 ng/mL/mo). Biopsy revealed aggressive prostate cancer (Gleason score 5 + 5). Staging with 18F-fluorocholine PET/CT (18F-FCH PET/CT) demonstrated lymph node metastasis. After 6 months of hormonal therapy with goserelin, PSA decreased to 0.38 ng/mL. A 18F-FCH PET/CT restaging scan demonstrated a global reduction of 18F-FCH lesion uptake with disappearance of some mediastinal and iliac pelvic lymph node activity.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.